Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

To the Minister of Medical Care and Sports
PO Box 20350
2500 EJ THE HAGUE

2020046548

National Health Care Institute
Care

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact
Dr T.H.L. Tran
T +31 (0)6-12001412

Date 5 November 2020
Subject GVS advice glucagon nasal powder (Baqsimi®)

Our reference
2020046548

Dear Ms van Ark,

In your letter of 9 June 2020 (CIBG-20-0554), you requested the National Health Care Institute (Zorginstituut Nederland) to assess whether the product glucagon nasal powder (Baqsimi®) is interchangeable with another product that is included in the Medicine Reimbursement System (GVS). The National Health Care Institute, advised by the Scientific Advisory Board (WAR), has completed this assessment. The considerations are included in the GVS report attached to this letter.

Glucagon nasal powder is indicated for the treatment of severe hypoglycaemia in adults, adolescents and children aged 4 and over with diabetes mellitus. It is available as a single-dose container with 3 mg of glucagon nasal powder. The recommended dose is 3 mg of glucagon administered in one nostril.

Assessment of interchangeability In the GVS, the blood glucose-increasing medicinal product glucagon (Glucagen®, Glucagen hypokit®) is included for the indication 'severe hypoglycaemia in diabetes mellitus'.

In the GVS, the classification of medicinal products into groups of interchangeability distinguishes between, among other criteria, medicinal products administered through injection and non-injection medicinal products.
For this reason, glucagon nasal powder and intramuscular glucagon are by definition not interchangeable.

Based on the above, glucagon nasal powder cannot be placed on List 1A. It should be assessed whether glucagon nasal powder is eligible for inclusion on List 1B.

Therapeutic value
The National Health Care Institute has come to the final conclusion that glucagon nasal powder has added therapeutic value in comparison to intramuscular glucagon in the treatment of severe hypoglycaemia in children (4 years and older), adolescents and adults with diabetes mellitus. There is a difference in ease of use between nasal and intramuscular glucagon. The National Health Care Institute sees added value for glucagon nasal powder because of its ease of use in acute situations, which prevents underuse of intramuscular glucagon.

Budget impact analysis
Inclusion of glucagon nasal powder (Baqsimi®) in the treatment of severe hypoglycaemia in diabetes mellitus on the GVS List 1B will be accompanied by additional costs estimated at a minimum of €3.5 to a maximum of €7.9 million in the third year after inclusion in the basic insured package.

Pharmaco-economic analysis
Based on the estimated budget impact, the product is exempt from pharmaco-economic analysis.

Advice
The National Health Care Institute advises including glucagon nasal powder (Baqsimi®) on List 1B, on the basis of the above considerations.

Yours sincerely,

Sjaak Wijma
Chair of the Executive Board

National Health Care Institute
Care I

Date
05 November 2020

Our reference
2020046548